Souhaitez-vous accéder aux communiqués récents ?

Operating loss from continuing operations for the year ended December 31, 2012 was $21.2 million, including $1.8 million in stock-based compensation. NeuVax™ (nelipepimut-S or E75)...

LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...

LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...

NEEDHAM, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported financial results for the fourth quarter and the year ended December 31, 2012. Celldex...

CHICAGO, IL--(Marketwire - Mar 6, 2013) - SpringCM®, the leader in Content Cloud Services for the enterprise, announced today the appointment of Chuck Teubner as executive chairman of...

LEXINGTON, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today...

TUSTIN, CA and HUNTINGTON BEACH, CA--(Marketwire - Feb 26, 2013) - Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will present two...

LEXINGTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...

Study published in NEJM today and presented tomorrow met primary endpoint[1] in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU)  Up to two-thirds (66%) of omalizumab...

WASHINGTON, Feb. 20, 2013 (GLOBE NEWSWIRE) -- Why should you wear blue? That's the question the Colon Cancer Alliance wants communities, businesses and individuals across the United States to answer...